Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Skye Bioscience Inc
SKYE
Healthcare
Biotechnology
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The...
company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:SKYE)
New Post
View:
Posts & Comments
Threaded Posts
(7)
•••
snowtrac
X
Post by
snowtrac
on Apr 10, 2024 11:20am
Great news
Great news we're off the OTC and on the Nasdaq tomorrow morning April 11!! https://stockhouse.com/news/press-releases/2024/04/10/skye-bioscience-uplists-to-the-nasdaq-global-market
(145)
•••
Bullknit101
X
Post by
Bullknit101
on Oct 08, 2021 10:40pm
Cannabinoid Manufacturing
Worth skipping to minute 29:30: https://youtu.be/44fFn8aD3Zo
BioVaxys & Adiverna Enter Collaboration to Develop Companion Animals Vaccines
posted Mar 10, 2026 9:00am by
BioVaxys Technology Corp.
-
|
“We are very excited to be working with Adiverna to develop what could be the world’s first mRNA veterinary vaccine. We believe the clinically proven advantages of the DPX platform formulated with Adiverna’s AI-designed mRNA sequences will provide for a superior product, adds Kovan. “With demonstrated in vivo proof of concept of DPX mRNA formulations, this ‘proof of product’ will further our partnering discussions utilizing DPX mRNA formulations in human therapeutic applications.” ...read more
(41)
•••
Stockqueen77
X
Post by
Stockqueen77
on Aug 09, 2021 11:01am
Press release
Punit Dhillon..you should do a press release how successful you and your uncle are by stealing shareholder money!
(41)
•••
Stockqueen77
X
Comment by
Stockqueen77
on Aug 05, 2021 11:23pm
RE:The arrest of AVTAR DHILLON
Punit Dhillon sat as a director of Arch Therapeutics...wonder if he'll be sitting beside his uncle and his mentor Avtar Dhillon, the one who taught him how to scam people.
(41)
•••
Stockqueen77
X
Post by
Stockqueen77
on Aug 05, 2021 4:15pm
The arrest of AVTAR DHILLON
Cannabis and Biotech Board Chair Arrested for Securities Fraud BY BRE BRADHAM Aug. 5, 2021, 8:47 AM Listen A cannabis and biotechnology entrepreneur was arrested and charged with securities fraud over
...more
(41)
•••
Stockqueen77
X
Post by
Stockqueen77
on Jul 14, 2021 2:30pm
Where is this company located
Where are they conducting these trials?...maybe Punit the CEO can answer this question if hes not to busy training or writing a book.
(41)
•••
Stockqueen77
X
Post by
Stockqueen77
on Jul 08, 2021 7:08pm
Look what I found...
https://www.accesswire.com/635483/INVESTIGATION-ALERT-Fields-Kupka-Shukurov-LLP-Is-Investigating-Skye-Bioscience-Inc-for-Potential-Breach-of-Fiduciary-Duty-Claims
(4)
•••
robertwfb
X
Post by
robertwfb
on Jun 02, 2021 2:15pm
anyone home?
quite the run on some very high volume. surprised there is not at least some small reaction on this board.
(4)
•••
robertwfb
X
Comment by
robertwfb
on Apr 09, 2021 2:49pm
RE:RE:RE:so whats up?
so how about a link to the law suits, thanks
(41)
•••
Stockqueen77
X
Comment by
Stockqueen77
on Mar 25, 2021 5:40pm
RE:RE:so whats up?
Not only is Punit Dhillon CEO, but JIM HEPPELL is on the board of directors, I wonder why people keep investing in their companies. Punit Dhillon, Avtar Dhillon and Jim Heppell and the parent company
...more
(121)
•••
JMark80
X
Comment by
JMark80
on Sep 25, 2020 8:03pm
RE:so whats up?
Wow. Anyone who read my last post should have bailed on this scam. Punit is CEO! Latest financing was 116.67mm shares at $.06, plus full warrant at $.06 that are good for 5 years!
(4)
•••
robertwfb
X
Post by
robertwfb
on Jun 29, 2020 4:56pm
so whats up?
so whats up with embi? lots action the last few days, but I have not seen anything going on. anyone heard any thing?
(121)
•••
JMark80
X
Comment by
JMark80
on Jun 02, 2020 7:43pm
RE:Dilution
Dilution is just one reason. When I first researched Nemus in 2015 the number of shares outstanding was ~15mm, and phase 1 for glaucoma was supposed to be conducted in 2017. CEO was replaced with the
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Team spotlight: Q+A: Charlene Duffett, Viridian Metals exploration manager
Freegold Ventures reports results from six additional drill holes at its Golden Summit project
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
Podcasts